NantKwest is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer and viral infectious diseases. NK cells are the body's first line of defense due to their innate ability to seek and destroy abnormal cells, such as cancer or virally infected cells, without prior exposure or activation by other support molecules required to train and activate adaptive immune cells such as T-Cells. Co. holds the exclusive right to commercialize activated NK cells, a commercially viable natural killer cell line, and a range of genetically modified derivatives capable of killing cancer and virally infected cells. The NK average annual return since 2015 is shown above.
The Average Annual Return on the NK average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NK average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NK average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|